EANS-Adhoc: - Development of earnings in financial year 2008/2009 falls short of expectations due to one-time effects - Occupancy rate remains at high level of 92.5 % - First quarter of 2009/2010 sh

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

annual report

30.10.2009

Berlin, 30 October 2009. Marseille-Kliniken AG (Prime Standard, ISIN
DE 0007783003, MKA) was able to increase operating turnover as
planned by 3.2 % to EUR 235.5 million (previous year: EUR 228.1
million) according to audited figures for the financial year
2008/2009 (1 July 2008 - 30 June 2009). However, Group net income
after minority interest decreased from EUR 13.7 million in the
previous year to EUR -13.5 million. This correlates to earnings per
share of EUR -1.12 against EUR 1.13 last year. EBIT/IFRS fell
considerably short of the company´s expectations, amounting to EUR
-6.8 million after being reported at EUR 22.5 million including
one-time effects in the previous year. EBITDAR was down from EUR 73.8
million to EUR 50.6 million year-on-year. Equity fell from EUR 82.5
million to EUR 62.6 million, which represents an equity ratio of 27.6
% after the previous year´s 34.2 %. Net debt amounted to EUR 74.3
million against EUR 68.1 million in the previous financial year.

However, comparing current earnings figures with those of the
previous financial year only has limited significance. In the
previous year, the Group generated an extraordinary gain from the
sale of property worth EUR 19.6 million as well as from the reversal
of deferred tax obligations recorded in profit or loss amounting to
EUR 4.9 million as a result of the corporate tax reform act 2008.
This year´s earnings were also negatively hit to the tune of EUR 8.6
million from one-off write-downs on fixed assets and receivables (EUR
4.1 million), process costs (EUR 1.1 million), tax audits (EUR 2.0
million) and additional non-recurring items (EUR 1.4 million).

In the financial year 2008/2009, earnings in operations were also
impacted considerably stronger than in the previous year. This mainly
stemmed beside start up costs for expansion facilities from increased
expenses for energy (EUR 1.8 million) and personnel recruitment as
well as the valuation of pension provisions result (in total EUR 2.7
million).

Adjusted Group net income according to DVFA/SG (IFRS) amounted to EUR
1.6 million in the period under review (previous year: EUR 11.1
million). Adjusted EBITDAR totalled EUR 55.2 million compared to EUR
62.6 million previously, while adjusted EBIT amounted to EUR 6.8
million against EUR 17.8 million in the previous year.

In spite of capacity increasing by 186 to a total of 9,085 beds, the
occupancy rate at Group level remains at a high level of 92.5 %
(previous year: 92.4 %). Due to the decline in earnings, at the
Annual General Meeting on 18 December 2009 in Berlin the Management
Board and Supervisory Board will propose to carry forward net profit
to a new account and waive a dividend payment for the financial year
2008/2009.

Marseille-Kliniken AG is publishing the complete financial report for
the financial year 2008/2009 today on its website at
www.marseille-kliniken.de.

The first quarter of 2009/2010 is developing positively in line with
expectations. As a result, the occupancy rate of bed capacities
increased to 92.8 % (previous year: 92.6 %). This enabled us to
increase turnover in the period under review by 6.4 % from EUR 58.0
million to EUR 61.7 million. The EBIT figure improved by EUR 0.4
million to EUR 3.9 million. This was due to the positive impact of
reduced start up losses from expansion facilities as well as cost
cutting measures taken for personnel and non-personnel costs.
Adjusted EBIT according to DVFA amounts to EUR 5.2 million and is EUR
0.6 million under the figure for the previous year´s period. The EBT
figure improved by EUR 0.4 million to EUR 2.9 million. Detailed
information can be found in the report on the first quarter that will
be published on the company website on 10 November 2009.

End of ad hoc release

Ende der Mitteilung euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Marseille-Kliniken AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marseille-Kliniken AG

Axel Hölzer

CEO

Alte Jakobstraße 79/80

10709 Berlin

Germany

Tel.: +49 - (0)30 / 246 32-400

Fax: +49 - (0)30 / 246 32-401

www.marseille-kliniken.com

Hillermann Consulting

Christian Hillermann

Investor Relations for Marseille-Kliniken AG

Poststraße 14/16

20354 Hamburg

Germany

Tel.: +49 - (0)40 / 320 279-10

Fax: +49 - (0)40 / 320 279-114

www.hillermann-consulting.de

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hamburg / regulated dealing